They say that any publicity is good publicity. Emergent BioSolutions (NYSE: EBS) might disagree after its highly publicized COVID-19 vaccine manufacturing problems. In this Motley Fool Live video recorded on June 23, Motley Fool contributors Keith Speights and Brian Orelli answer a viewer’s question about whether or not Emergent BioSolutions can recover from its recent blunders.